The World Health Organization (WHO) has launched its Global Influenza Strategy for 2019-2030, its most comprehensive strategy to date against the infectious disease.
11 March 2019 News
7 March 2019 News
During a House of Commons Health and Social Care Committee witness session on the availability of Vertex’s Orkambi and other cystic fibrosis (CF) drugs on the National Health Service (NHS),...
6 March 2019 News
Boston-based pharmaceutical company Vertex has published promising interim analysis from two Phase III studies of a triple combination therapy of VX-445, tezacaftor and ivacaftor for cystic fibrosis.
19 February 2019 News
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase (ALK) positive...
4 February 2019 Analysis
Air pollution is a leading cause of death globally, as well as being responsible for new cases of chronic respiratory illnesses, such as asthma and COPD, and lung cancer, it...
4 February 2019 News
Patient-led campaign organisation Just Treatment has written to the UK Prime Minister Theresa May and Secretary of State for Health and Social Care Matt Hancock calling on the government to...
31 January 2019 Analysis
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
30 January 2019 Comment
Globally, there are 9,052 marketed products for ENT disorders. Most of these pharmaceuticals are small molecules and generics that target G protein-coupled receptors (GPCRs), nuclear receptors, and microbial membranes.